Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Kidney International|June 29, 2021
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)Ronald D Perrone, Kaleab Z Abebe, Terry J Watnick, et al.
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 22, 2011
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres, Esther Meijer, Kyongtae T Bae, et al.
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2020
Toward Patient-Centered Innovation: A Conceptual Framework for Patient-Reported Outcome Measures for Transformative Kidney Replacement DevicesJennifer E Flythe, Tandrea S Hilliard, Kourtney Ikeler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 4, 2016
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trialMaría V Irazabal, Kaleab Z Abebe, Kyongtae Ty Bae, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 20, 2015
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)Ronald D Perrone, Jon Neville, Arlene B Chapman, et al.
Kidney International Reports|December 18, 2019
Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease PatientsMark R Hanudel, Isidro B Salusky, Renata C Pereira, et al.
Kidney International|March 19, 2015
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceArlene B Chapman, Olivier Devuyst, Kai-Uwe Eckardt, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Kidney International|June 29, 2021
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)Ronald D Perrone, Kaleab Z Abebe, Terry J Watnick, et al.
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 22, 2011
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres, Esther Meijer, Kyongtae T Bae, et al.
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2020
Toward Patient-Centered Innovation: A Conceptual Framework for Patient-Reported Outcome Measures for Transformative Kidney Replacement DevicesJennifer E Flythe, Tandrea S Hilliard, Kourtney Ikeler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 4, 2016
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trialMaría V Irazabal, Kaleab Z Abebe, Kyongtae Ty Bae, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 20, 2015
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)Ronald D Perrone, Jon Neville, Arlene B Chapman, et al.
Kidney International Reports|December 18, 2019
Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease PatientsMark R Hanudel, Isidro B Salusky, Renata C Pereira, et al.
Kidney International|March 19, 2015
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceArlene B Chapman, Olivier Devuyst, Kai-Uwe Eckardt, et al.
Pageof 13